"Author, Year",Title,Journal,Reason,Subreason
"Aalbers, 2015",Intra-articular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating tnf as a potential therapeutic target for local treatment,"Joint, bone, spine",Outcomes,No outcomes of interest at 24 weeks
"Abe, 2006","A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in japanese patients with rheumatoid arthritis",Journal of rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Abu-Zaid, 2018","The effectiveness of etanercept and adalimumab on anemia of chronic disease and serum hepcidin in patients with rheumatoid arthritis, a comparative study",Egyptian Rheumatologist,Study design,Non-interventional
"Allaart, 2007",Treatment of recent-onset rheumatoid arthritis: Lessons from the best study,Journal of rheumatology.,Population,cDMARD na夫e
"Alten, 2018",Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: A descriptive analysis of data from interventional trials and the real-world setting,Arthritis Research & Therapy,Outcomes,No outcomes of interest at 24 weeks
"Alten, 2019","Randomised, double-blind, phase iii study comparing the infliximab biosimilar, pf-06438179/gp1111, with reference infliximab: Efficacy, safety and immunogenicity from week 30 to week 54",Open Heart,Outcomes,No outcomes of interest at 24 weeks
"Alten, 2017","Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (ra-beam)",Der internist,Other,Language
"Anonymous, 2003",Adalimumab (humira) for rheumatoid arthritis,Medical Letter on Drugs & Therapeutics,Study design,Review
"Anonymous, 2010",Tocilizumab (actemra) for rheumatoid arthritis,Medical Letter on Drugs & Therapeutics,Study design,Review
"Anonymous, 2017",Sarilumab (kevzara) for rheumatoid arthritis,Medical Letter on Drugs and Therapeutics,Study design,Review
"Anonymous, 2018",Baricitinib (olumiant) for rheumatoid arthritis,Medical Letter on Drugs & Therapeutics,Study design,Review
"Antoni, 1999",Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis,Clinical and experimental rheumatology,Study design,Review
"Apsangikar, 2018","A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate",Indian Journal of Rheumatology,Intervention,Not of interest
"Bae, 2013",Improved health outcomes with etanercept versus usual dmard therapy in an asian population with established rheumatoid arthritis,BMC musculoskeletal disorders,Outcomes,No outcomes of interest at 24 weeks
"Bankhurst, 1999",Etanercept and methotrexate combination therapy,Clinical and experimental rheumatology,Study design,Not of interest
"Bao, 2016",Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist,International journal of rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Bao , 2016",Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist,International Journal of Rheumatic Diseases,Outcomes,No outcomes of interest at 24 weeks
"Bathon, 2000",A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis,New England journal of medicine,Population,cDMARD na夫e
"Bay-Jensen, 2014",Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline,Journal of Clinical Rheumatology,Outcomes,No outcomes of interest
"Bazzichi, 2019",Subcutaneous tocilizumab alone or with a csdmard in rheumatoid arthritis patients: Subanalysis of italian data from a multicenter phase iiib/iv trial,Clinical Rheumatology,Study design,Non-comparative post-hoc analysis
"Beals, 2017","Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring",Plos one,Outcomes,No outcomes of interest at 24 weeks
"Bingham, 2015","Maintenance of clinical and radiographic benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: Week-112 efficacy and safety results of the open-label long-term extension of a phase iii, double-blind, randomized, placebo-controlled trial",Arthritis Care and Research,Outcomes,No outcomes of interest at 24 weeks
"Bingham, 2015",Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: Results of a randomised controlled trial (visara),Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest at 24 weeks
"Bobbio-Pallavicini, 2007",High iga rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis,Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest
"Boers, 2001",Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the american college of rheumatology 20% criteria: The paradox of beneficial treatment effects in nonresponders in the attract trial. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy,Arthritis & Rheumatism,Study design,Review
"Boyle, 2015",The jak inhibitor tofacitinib suppresses synovial jak1-stat signalling in rheumatoid arthritis,Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Breedveld, 2005",Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis,Annals of the rheumatic diseases,Outcomes,No outcomes of interest
"Bresnihan, 1999",Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist,--,Outcomes,No outcomes of interest at 24 weeks
"Bresnihan, 2002",Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis,--,Study design,Review
"Bresnihan , 1998",Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist,Arthritis & Rheumatism,Population,cDMARD na夫e
"Buch, 2019",Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse tnf-inhibitor-induced antinuclear autoantibody/ double-stranded DNA autoantibody conversion? An analysis of the ample and attest trials,Clinical and Experimental Rheumatology,Outcomes,No outcomes of interest
"Burmester, 2016",Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional dmards in patients with ra at week 97 (summacta),Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Burmester, 2017","Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled function trial",Annals of the rheumatic diseases,Population,cDMARD na夫e
"Bykerk, 2012","Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to dmards and/or tnf inhibitors: A large, open-label study close to clinical practice",Annals of the Rheumatic Diseases,Study design,Non-interventional
"Calguneri, 1999",Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis,Clinical and experimental rheumatology,Population,cDMARD na夫e
"Campion , 1996",Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The il-1ra arthritis study group,Arthritis & Rheumatism,Population,cDMARD na夫e
"Carubbi, 2016",Safety and efficacy of intra-articular anti-tumor necrosis factor alpha agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare,International Journal of Immunopathology and Pharmacology,Comparator,Corticosteroids
"Cella, 2005",Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis,Journal of Rheumatology,Study design,Non-comparative post-hoc
"Charles, 2000","Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials",Arthritis & Rheumatism,Outcomes,No outcomes of interest
"Charles-Schoeman, 2017",Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial,Arthritis & rheumatology,Population,cDMARD na夫e
"Chen, 2009","Randomized, double-blind, placebo-controlled, comparative study of human anti-tnf antibody adalimumab in combination with methotrexate and methotrexate alone in taiwanese patients with active rheumatoid arthritis",Journal of the Formosan Medical Association,Outcomes,No outcomes of interest at 24 weeks
"Chen, 2006",The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis,Annals of the rheumatic diseases,Outcomes,No outcomes of interest
"Choe, 2017","A randomised, double-blind, phase iii study comparing sb2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Choy, 2002","Efficacy of a novel pegylated humanized anti-tnf fragment (cdp870) in patients with rheumatoid arthritis: A phase ii double-blinded, randomized, dose-escalating trial",Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Choy, 2008",Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis,Annals of the rheumatic diseases,Intervention,Ciclosporin
"Cohen, 2004",Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis,Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest
"Cohen, 2016",A phase i pharmacokinetics trial comparing pf-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis,British journal of clinical pharmacology,Outcomes,No outcomes of interest
"Collison, 2018",Selective inhibition of jak1 shows promise for ra,Nature Reviews Rheumatology,Study design,Review
"Combe, 2014",Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: Results of the go-more study,Annals of the rheumatic diseases,Population,Low disease activity population
"Conaghan, 2013","Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The asset randomised controlled trial",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Coombs, 2010","Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with cp-690,550, an orally active janus kinase (jak) inhibitor: Results from a randomised, double-blind, placebo-controlled trial",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Cuomo, 2006",A comparison between the simplified disease activity index (sdai) and the disease activity score (das28) as measure of response to treatment in patients undergoing different therapeutic regimens,Reumatismo,Other,Language
"de Jong, 2013",Induction therapy with a combination of dmards is better than methotrexate monotherapy: First results of the treach trial,Annals of the rheumatic diseases,Population,cDMARD na夫e
"De Stefano, 2010",Comparison of combination therapies in the treatment of rheumatoid arthritis: Leflunomide-anti-tnf-alpha versus methotrexate-anti-tnf-alpha,Clinical rheumatology,Intervention,Unspecified treatment
"Dehoratius, 2018",Satisfaction with subcutaneous golimumab and its auto-injector among rheumatoid arthritis patients with inadequate response to adalimumab or etanercept,The Patient: Patient-Centered Outcomes Research,Outcomes,No outcomes of interest
"den Broeder, 2002","A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (d2e7) in patients with rheumatoid arthritis",Journal of rheumatology,Outcomes,No outcomes of interest
"Deodhar, 2016",The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis,Clinical rheumatology,Outcomes,No outcomes of interest
"Detert, 2016","Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis",Clinical & Experimental Rheumatology,Study design,Non-randomized
"Dischereit, 2013",Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: A prospective 2-year study,Clinical rheumatology,Study design,Non-randomized
"Domanska, 2017",Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis,Expert opinion on drug delivery,Outcomes,No outcomes of interest
"Duan, 2015",Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: A randomized controlled trial,Clinical rheumatology,Population,cDMARD na夫e
"Durez, 2007","Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone",Arthritis and rheumatism,Population,cDMARD na夫e
"Egeth, 2017",Patient and healthcare professionals preference for brenzys vs. Enbrel autoinjector for rheumatoid arthritis: A randomized crossover simulated-use study,Advances in therapy,Outcomes,No outcomes of interest
"Emery, 2015","Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled avert study of 24 months, with a 12-month, double-blind treatment period",Annals of the rheumatic diseases,Population,cDMARD na夫e
"Emery, 2010",Impact of t-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the adjust trial),Annals of the Rheumatic Diseases,Population,Undifferentiated arthritis
"Emery, 2006",Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life,Journal of rheumatology,Outcomes,No outcomes of interest
"Emery, 2017",52-week results of the phase 3 randomized study comparing sb4 with reference etanercept in patients with active rheumatoid arthritis,Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Engvall, 2010",Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: A randomised study over 21 months,Arthritis research & therapy,Population,cDMARD na夫e
"Eriksson, 2013",Biological vs. Conventional combination treatment and work loss in early rheumatoid arthritis: A randomized trial,JAMA internal medicine,Population,cDMARD na夫e
"Eriksson, 2016",Infliximab versus conventional combination treatment and seven-year work loss in early rheumatoid arthritis: Results of a randomized swedish trial,Arthritis Care and Research,Population,cDMARD na夫e
"Fernandez-Nebro, 2005",Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists,American Journal of Medicine,Study design,Non-randomized
"Ferraccioli, 2002","Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: Results of an open trial",Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Fleischmann, 2012",Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis,New England journal of medicine,Comparator,No active comparator at 24 weeks (placebo crossover only)
"Fleischmann , 2017","Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial","Lancet (london, england)",Duplicate publication,--
"Fleischmann , 2003","Anakinra, a recombinant human interleukin-1 receptor antagonist (r-methuil-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial",Arthritis and Rheumatism,Population,cDMARD na夫e
"Furst, 2007","Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The opposite study",Annals of the rheumatic diseases,Study design,Pilot study
"Furst, 2015",Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis,Arthritis Care and Research,Intervention,Discontinuation/withdrawal study
"Galarraga, 2009",Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis,Rheumatology,Outcomes,No outcomes of interest
"Gao, 2010",Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis,Nan fang yi ke da xue xue bao [Journal of Southern Medical University],Other,Language
"Gashi, 2014",Treatment of rheumatoid arthritis with biologic dmards (rituximab and etanercept),Medical archives,Outcomes,No outcomes of interest
"Genovese, 2002",Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes,Arthritis and rheumatism,Population,cDMARD na夫e
"Genovese, 2017","Peficitinib, a jak inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis",Arthritis & rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Genovese, 2011","Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase ii, randomized, placebo-controlled, dose-finding trial",Arthritis and Rheumatism,Intervention,Atacicept
"Genovese, 2016","Efficacy and safety of abt-494, a selective jak-1 inhibitor, in a phase iib study in patients with rheumatoid arthritis and an inadequate response to methotrexate",Arthritis & rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Genovese , 2004",Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate,Arthritis and Rheumatism,Comparator,Etanacerpt monotherapy vs. etanercept + anakinra
"Gerards, 2003",Cyclosporin a monotherapy versus cyclosporin a and methotrexate combination therapy in patients with early rheumatoid arthritis: A double blind randomised placebo controlled trial,Annals of the Rheumatic Diseases,Intervention,Cyclosporin
"Gerlag, 2010","Preclinical and clinical investigation of a ccr5 antagonist, azd5672, in patients with rheumatoid arthritis receiving methotrexate",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Gerlag, 2019",Effects of b-cell directed therapy on the preclinical stage of rheumatoid arthritis: The prairi study,Annals of the Rheumatic Diseases,Population,Preclinical RA
"Goekoop-Ruiterman, 2005","Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): A randomized, controlled trial",Arthritis and rheumatism,Population,cDMARD na夫e
"Gomez-Garcia, 2013",Reduced numbers of circulating cd28-negative cd4+ cells in patients with rheumatoid arthritis chronically treated with abatacept,International journal of rheumatic diseases,Outcomes,No outcomes of interest
"Gonzalez-Juanatey, 2006",Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis,Arthritis & Rheumatism,Study design,Non-randomized
"Gottenberg, 2016",Nontnf-targeted biologic vs a second anti-tnf drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-tnf drug: A randomized clinical trial,Journal of the American Medical Association,Intervention,Unspecified treatment
"Guler-Yuksel, 2008","Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis",Annals of the rheumatic diseases,Population,cDMARD na夫e
"Hara, 2007","Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: A controlled, multicenter, double-blind, parallel-group study",Modern rheumatology,Population,cDMARD na夫e
"Haraoui, 2011",Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The reset trial,Journal of Rheumatology,Study design,Single-arm
"Haugeberg, 2009","Bone loss in patients with active early rheumatoid arthritis: Infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study",Annals of the rheumatic diseases,Population,cDMARD na夫e
"Hazlewood, 2012",Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis,Journal of Clinical Rheumatology,Study design,Observational
"Heath, 2010",Selective depletion of b lymphocytes with rituximab preserves b-cell function,Nature Reviews Endocrinology,Study design,Review
"Heimans, 2013",Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: Results of the improved study,Arthritis Research and Therapy,Population,Undifferentiated/early RA
"Huang, 2009","Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: A multi-center randomized, double-blind, placebo-controlled clinical study",Zhonghua nei ke za zhi [Chinese journal of internal medicine],Other,Language
"Huizinga, 2014","Sarilumab, a fully human monoclonal antibody against il-6r[alpha] in patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised saril-ra-mobility part a trial",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Huizinga, 2014","Sarilumab, a fully human monoclonal antibody against il-6ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised saril-ra-mobility part a trial",Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest at 24 weeks
"Jani, 2016","A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (exemptia; zrc-3197) and adalimumab (humira) in patients with rheumatoid arthritis",International journal of rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Jiang , 2000","A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores",Arthritis & Rheumatism,Outcomes,No outcomes of interest
"Jones, 2010",Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The ambition study,Annals of the rheumatic diseases,Population,cDMARD na夫e
"Kaeley, 2018",Similar improvements in patient-reported outcomes among rheumatoid arthritis patients treated with two different doses of methotrexate in combination with adalimumab: Results from the musica trial,Rheumatology and Therapy,Intervention,Dose randomization
"Kaine, 2012","Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: Impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase iiib allow study)",Annals of the rheumatic diseases,Intervention,Discontinuation/withdrawal study
"Kastanek, 2002",Using anakinra for adult rheumatoid arthritis,--,Study design,Review
"Kastbom, 2007",Fcgamma receptor type iiia genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis,Arthritis & Rheumatism,Study design,Non-randomized
"Kavanaugh, 2008",Assessment of rituximab's immunomodulatory synovial effects (arise trial). 1: Clinical and synovial biomarker results,Annals of the Rheumatic Diseases,Study design,Single-arm trial
"Kay, 2008","Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Keystone, 2003",Role of adalimumab in the treatment of early rheumatoid arthritis,Clinical and experimental rheumatology,Population,subanalysis of early RA
"Keystone, 2015",Two-year radiographic and clinical outcomes from the canadian methotrexate and etanercept outcome study in patients with rheumatoid arthritis,Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Keystone, 2016",Two-year radiographic and clinical outcomes from the canadian methotrexate and etanercept outcome study in patients with rheumatoid arthritis,Rheumatology,Intervention,Dose tapering
"Keystone, 2004","Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Keystone, 2015",Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate,Annals of the rheumatic diseases,Comparator,No active comparator at 24 weeks (placebo crossover only)
"Keystone, 2009",Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies,Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Kim, --",Randomized comparison of etanercept with usual therapy in an asian population with active rheumatoid arthritis: The appeal trial,International Journal of Rheumatic Diseases.,Outcomes,No outcomes of interest at 24 weeks
"Kim, 2012",Randomized comparison of etanercept with usual therapy in an asian population with active rheumatoid arthritis: The appeal trial,International journal of rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Kim, 2013",A clinical trial and extension study of infliximab in korean patients with active rheumatoid arthritis despite methotrexate treatment,Journal of korean medical science,Study design,No outcomes of interest at 24 weeks
"Kirkham, 2014","Effects of golimumab, an anti-tumour necrosis factor-alpha human monoclonal antibody, on lipids and markers of inflammation",Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest at 24 weeks
"Kivitz, 2018",Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis,Rheumatology and Therapy,Intervention,Dose randomization
"Kivitz, 2006","Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: The touch trial",Clinical Therapeutics,Study design,Single-arm trial
"Kivitz, 2018",Two-year efficacy and safety of subcutaneous tocilizumab in combination with disease-modifying antirheumatic drugs including escalation to weekly dosing in rheumatoid arthritis,Journal of Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Kosinski, 2002",Health-related quality of life in early rheumatoid arthritis: Impact of disease and treatment response,American journal of managed care,Population,cDMARD na夫e
"Kremer, 2009","The safety and efficacy of a jak inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase iia trial of three dosage levels of cp-690,550 versus placebo",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Kremer, 2004",Benefit/risk of leflunomide in rheumatoid arthritis,Clinical and Experimental Rheumatology,Study design,Review
"Kremer, 2016","A phase iib study of abt-494, a selective jak-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy",Arthritis & rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Lan, 2004","A comparative study of etanercept plus methotrexate and methotrexate alone in taiwanese patients with active rheumatoid arthritis: A 12-week, double-blind, randomized, placebo-controlled study",Journal of the Formosan Medical Association,Study design,No outcomes of interest at 24 weeks
"Langer, 2003",Kineret: Efficacy and safety in daily clinical practice: An interim analysis of the kineret response assessment initiative (kreative) protocol,International Journal of Clinical Pharmacology Research,Study design,Observational
"Lazzerini, 2008","Arrhythmic risk during acute infusion of infliximab: A prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis",Journal of Rheumatology,Outcomes,No outcomes of interest
"Lindegaard, 2016",Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious,Scandinavian journal of rheumatology,Intervention,Dose-randomization
"Lisbona, 2008",Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks,Journal of rheumatology,Outcomes,No outcomes of interest
"Lu, 2009","Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with t-614 compared with methotrexate",Arthritis and rheumatism,Population,cDMARD na夫e
"Lu, 2008","Safety and efficacy of t-614 in the treatment of patients with active rheumatoid arthritis: A double blind, randomized, placebo-controlled and multicenter trial",Chinese medical journal,Population,cDMARD na夫e
"MacIsaac, 2014",Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients,Plos one,Outcomes,No outcomes of interest at 24 weeks
"Maini, 1998",Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis,Arthritis and rheumatism,Outcomes,No outcomes of interest
"Maini, 2006","Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Malottki, 2011","Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation",Health Technology Assessment,Study design,Systematic literature review
"Manders, 2015","Cost-effectiveness of abatacept, rituximab, and tnfi treatment after previous failure with tnfi treatment in rheumatoid arthritis: A pragmatic multi-centre randomised trial",Arthritis research & therapy,Intervention,Unspecified treatment
"Mandl, 2012","Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: Results of a multicenter, randomized study",Arthritis and rheumatism,Outcomes,No outcomes of interest
"Matsuno, 2018",A randomized double-blind parallel-group phase iii study to compare the efficacy and safety of ni-071 and infliximab reference product in japanese patients with active rheumatoid arthritis refractory to methotrexate,Modern Rheumatology.,Outcomes,No outcomes of interest at 24 weeks
"Mazurov, 2014",The quality of life in patients with rheumatoid arthritis treated with rituximab,Klinicheskaia meditsina,Other,Language
"Mease, 2010",Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: Results from the sunrise trial,Journal of rheumatology,Intervention,Discontinuation/withdrawal study
"Migliore, 2012",May etanercept and pth (1-34) association heal erosions in early rheumatoid arthritis? A pilot study,European review for medical and pharmacological sciences,Intervention,Teriparatide
"Montecucco, 2005",In early rheumatoid arthritis the combination of methotrexate and infliximab over 2 years reduces the progression of radiological lesions more than methotrexate alone,Clinical & Experimental Rheumatology,Outcomes,No outcomes of interest
"Moreland, 2004",Adalimumab in rheumatoid arthritis,Current rheumatology reports,Other,Review
"Moreland, 2004",Infliximab in rheumatoid arthritis,Current rheumatology reports,Other,Review
"Moreland, 2006",Efficacy and safety of rituximab in rheumatoid arthritis patients refractory to methotrexate,Current Rheumatology Reports,Intervention,methylprednisone/prednisone combination therapies
"Moreland, 2006",Efficacy of costimulation blockade with abatacept in rheumatoid arthritis patients refractory to tumor necrosis factor-alpha inhibition,Current Rheumatology Reports,Other,Review
"Moreland, 2012",A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial,Arthritis and rheumatism,Population,cDMARD na夫e
"Mori, 2018",Tofacitinib therapy for rheumatoid arthritis: A direct comparison study between biologic-naive and experienced patients,Internal Medicine,Study design,Non-randomized
"Muller-Ladner, 2012",Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis,Zeitschrift fur rheumatologie,Study design,Pooled analysis
"Neva, 2000",Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations,Arthritis and rheumatism,Outcomes,No outcomes of interest
"O'Dell, 2002","Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial",Arthritis and rheumatism,Population,cDMARD na夫e
"Ostergaard, 2015","Mri assessment of early response to certolizumab pegol in rheumatoid arthritis: A randomised, double-blind, placebo-controlled phase iiib study applying mri at weeks 0, 1, 2, 4, 8 and 16",Annals of the rheumatic diseases,Comparator,No active comparator at 24 weeks (placebo crossover only)
"Pandi Kumar, 2018",A prospective study on comparing the efficacy of combination therapy and monotherapy of dmards in patients with rheumatoid arthritis,Research Journal of Pharmacy and Technology,Outcomes,No outcomes of interest at 24 weeks
"Pavelka, 2017",Maintenance of remission with combination etanercept-dmard therapy versus dmards alone in active rheumatoid arthritis: Results of an international treat-to-target study conducted in regions with limited biologic access,Rheumatology international,Population,Low disease activity population
"Porter, 2016","Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (orbit): An open-label, randomised controlled, non-inferiority, trial","Lancet (london, england)",Intervention,Unspecified treatment
"Quinn, 2005","Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial",Arthritis and rheumatism,Population,cDMARD na夫e
"Radstake, 2009",Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis,Annals of the Rheumatic Diseases,Study design,Non-randomized
"Raffeiner, 2013",Adopting low-dose etanercept strategy in the long-term management of rheumatoid arthritis patients,Clinical Drug Investigation,Study design,Review
"Ramos-Remus, 2008",The option trial: Inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis,Future Rheumatology,Other,Review
"Rau, 2004",Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate,Scandinavian journal of rheumatology,Study design,No outcomes of interest at 24 weeks
"Rexhepi, 2018",Evaluation of the efficacy of combined therapy of methotrexate and etanercept versus methotrexate as a mono-therapy,Open Access Macedonian Journal of Medical Sciences,Outcomes,No outcomes of interest at 24 weeks
"Rezaei, 2013",Evaluation of hand bone loss by digital x-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: Results from the swefot trial,BMC Musculoskeletal Disorders,Population,cDMARD na夫e
"Roshique, 2015",Efficacy and safety of a biosimilar rituximab in biologic naive patients with active rheumatoid arthritis,Clinical Rheumatology,Study design,Non-randomized
"Roux, 2011","Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: Double-blind, randomized pilot study",Journal of rheumatology,Comparator,Betamethasone
"Rubbert-Roth, 2010",Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase iii randomized study (mirror),Rheumatology,Intervention,Dose-randomization
"Russell, 2007",Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment,Annals of the rheumatic diseases,Outcomes,No outcomes of interest
"Saleem, 2008","Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?",Annals of the rheumatic diseases,Population,Undifferentiated arthritis
"Salgado, 2013",The jak inhibitor tofacitinib for active rheumatoid arthritis: Results from phase iii trials,International Journal of Clinical Rheumatology,Study design,Review
"Saunders, 2008","Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies",Arthritis and rheumatism,Population,cDMARD na夫e
"Schiff, 2014","Rheumatoid arthritis secondary non-responders to tnf can attain an efficacious and safe response by switching to certolizumab pegol: A phase iv, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Schiff, 2014",Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from ample trial,Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Scott, 2015",Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: Tacit non-inferiority randomised controlled trial,BMJ,Outcomes,No outcomes of interest at 24 weeks
"Sennels, 2008","Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa b ligand, and high-sensitivity c-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate",Scandinavian Journal of Rheumatology,Study design,No outcomes of interest at 24 weeks
"Shi, 2013","The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: A multi-center, randomized, double-blinded, placebo-controlled trial",Zhonghua nei ke za zhi [Chinese journal of internal medicine],Other,Language
"Smeets, 2003","Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Smolen, 2016",Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised exxelerate study,"Lancet (london, england)",Outcomes,No outcomes of interest at 24 weeks
"Smolen, 2017","A randomised, double-blind trial to demonstrate bioequivalence of gp2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis",Annals of the rheumatic diseases,Outcomes,No outcomes of interest
"Smolen, 2018","Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar sb2 compared with continuing reference infliximab and sb2 in patients with rheumatoid arthritis: Results of a randomised, double-blind, phase iii transition study",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Smolen, 2014",Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: The randomised controlled optima trial,"Lancet (london, england)",Population,cDMARD na夫e
"Smolen, 2014","Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: The certain double-blind, randomised, placebo-controlled trial",Annals of the Rheumatic Diseases.,Population,Low to moderate disease activity
"Smolen, 2015","Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: The certain double-blind, randomised, placebo-controlled trial",Annals of the rheumatic diseases,Population,cDMARD na夫e
"Smolen, 2005",Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study,Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Smolen, 2013","Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (preserve): A randomised controlled trial","Lancet (london, england)",Intervention,Discontinuation/withdrawal study
"Sonomoto, 2014",Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events,Rheumatology,Study design,Pooled analysis
"Soubrier, 2009",Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: Data from the guepard trial,Rheumatology,Population,cDMARD na夫e
"St Clair, 2002","The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from attract, a multicenter, randomized, double-blind, placebo-controlled trial",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Strand, 2015",Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to dmards,Arthritis Care and Research,Comparator,No active comparator at 24 weeks (placebo crossover only)
"Strand, 2015",Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: Patient-reported outcomes from a phase iii trial,Arthritis Care and Research,Outcomes,No outcomes of interest at 24 weeks
"Strand, 2015",The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios,International Journal of Clinical Rheumatology,Intervention,Discontinuation/withdrawal study
"Strand, 2009","Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the rapid 1 randomized controlled trial",Arthritis research & therapy,Outcomes,No outcomes of interest at 24 weeks
"Stubenrauch, 2010",Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody elisa using clinical adverse event-driven immunogenicity testing,Clinical Therapeutics,Study design,Pooled analysis
"Suh, 2019",Long-term efficacy and safety of biosimilar ct-p10 versus innovator rituximab in rheumatoid arthritis: 48-week results from a randomized phase iii trial,BioDrugs,Outcomes,No outcomes of interest at 24 weeks
"Sun, 2016",Efficacy and safety of combined etanercept and iguratimod for active rheumatoid arthritis,Biomedical Research (India),Population,cDMARD na夫e
"Tak, 2011",Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The image trial,Annals of the rheumatic diseases,Population,cDMARD na夫e
"Takeuchi, 2013","A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in japanese subjects with active rheumatoid arthritis",Modern rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Takeuchi, 2015",Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of ct-p13 and innovator infliximab in japanese patients with rheumatoid arthritis,Modern rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Tam, 2012",Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial,Journal of rheumatology,Population,cDMARD na夫e
"Tanaka, 2016","Efficacy and safety of baricitinib in japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: A 12-week, double-blind, randomized placebo-controlled study",Journal of rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Tanaka, 2018","Efficacy and safety of baricitinib in japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study",Modern rheumatology,Study design,Single-arm extension
"Tanaka, 2011","Phase ii study of tofacitinib (cp-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate",Arthritis Care and Research,Outcomes,No outcomes of interest at 24 weeks
"Tanaka, 2019","Modified- versus immediate-release tofacitinib in japanese rheumatoid arthritis patients: A randomized, phase iii, non-inferiority study",Rheumatology,Intervention,Dose randomization
"Tanaka, 2015","Efficacy and safety of tofacitinib as monotherapy in japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study",Modern rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Taylor, 2004","Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis",Arthritis and rheumatism,Outcomes,No outcomes of interest
"Taylor, 2006",Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis,Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Tony, 2019",Brief report: Safety and immunogenicity of rituximab biosimilar gp 2013 after switch from reference rituximab in patients with active rheumatoid arthritis,Arthritis Care and Research,Outcomes,No outcomes of interest
"Van De Putte, 2003","Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (d2e7) in dmard refractory patients with rheumatoid arthritis: A 12 week, phase ii study",Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest at 24 weeks
"van der Heijde, 2008",The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy,Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"van der Heijde, 2019","Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: Clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase iii study",Arthritis and Rheumatology.,Outcomes,No outcomes of interest at 24 weeks
"van der Kooij, 2009",Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis,Arthritis and rheumatism,Population,cDMARD na夫e
"van der Kooij, 2009","Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis",Annals of the rheumatic diseases,Population,cDMARD na夫e
"van Jaarsveld, 2000","Aggressive treatment in early rheumatoid arthritis: A randomised controlled trial. On behalf of the rheumatic research foundation utrecht, the netherlands",Annals of the rheumatic diseases,Population,cDMARD na夫e
"Van Riel, 2006",Efficacy and safely of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The adore study,Annals of the Rheumatic Diseases,Outcomes,No outcomes of interest at 24 weeks
"Van Riel, 2008",Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The adore trial,Annals of the Rheumatic Diseases,Study design,No outcomes of interest at 24 weeks
"van Riel, 2006",Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The adore study,Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"van Vollenhoven, 2009",Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (swefot trial): 1-year results of a randomised trial,"Lancet (london, england)",Population,cDMARD na夫e
"van Vollenhoven, 2011","Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase ii, randomized, placebo-controlled trial",Arthritis and rheumatism,Intervention,Atacicept
"van Vollenhoven, 2016","Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis",Annals of the rheumatic diseases,Population,Low disease activity population
"van Vollenhoven, 2015","Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: A phase ii, randomized, double-blind, placebo-controlled pilot trial",Arthritis & rheumatology,Intervention,atacicept
"Weinblatt, 2006","Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study",Arthritis and rheumatism,Outcomes,No outcomes of interest at 24 weeks
"Weinblatt, 2017","A phase iii study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis",Arthritis & rheumatology,Population,cDMARD na夫e
"Weinblatt, 2018",Switching from reference adalimumab to sb5 (adalimumab biosimilar) in patients with rheumatoid arthritis: Fifty-two-week phase iii randomized study results,Arthritis and Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Weinblatt, 2012",Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the realistic phase iiib study,Arthritis & rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Weinblatt, 2015","Twenty-eight-week results from the realistic phase iiib randomized trial: Efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population",Arthritis research & therapy,Outcomes,No outcomes of interest at 24 weeks
"Weinblatt, 2008","Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study",Arthritis and rheumatism,Intervention,Dose randomization
"Weinblatt, 2007",Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial,Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Weisman, 2003","Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study",Clinical therapeutics,Intervention,Dose randomization
"Weisman, 2007","A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases",Rheumatology ,Population,Restricted to patients with comorbidities
"Westhovens, 2006","A phase i study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis",Journal of rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Westhovens, 2015",Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis,Annals of the rheumatic diseases,Population,Low disease activity population
"Wijesinghe, 2017",Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: Results from a randomized double blind controlled clinical trial,BMC Musculoskeletal Disorders,Comparator,Leflunomide
"Williams, 2016","Comparative assessment of clinical response in patients with rheumatoid arthritis between pf-05280586, a proposed rituximab biosimilar, and rituximab",British journal of clinical pharmacology,Study design,Modelling study
"Wislowska, 2007",Preliminary evaluation in rheumatoid arthritis activity in patients treated with tnf-alpha blocker plus methotrexate versus methotrexate or leflunomide alone,Rheumatology International,Study design,Non-randomized
"Xia, 2016",Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects,Zeitschrift fur rheumatologie,Intervention,Iguaratimod
"Yoo, 2013","A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of ct-p13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The planetra study",Annals of the rheumatic diseases,Outcomes,No outcomes of interest at 24 weeks
"Yoo, 2016",A phase iii randomized study to evaluate the efficacy and safety of ct-p13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the planetra study,Arthritis research & therapy,Outcomes,No outcomes of interest at 24 weeks
"Yoo, 2017","A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of ct-p10 and innovator rituximab in patients with rheumatoid arthritis",Annals of the rheumatic diseases,Study design,Phase 1
"Yoo, 2017","Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar ct-p10 versus innovator rituximab in patients with rheumatoid arthritis: Results up to week 72 of a phase i randomized controlled trial",BioDrugs,Outcomes,No outcomes of interest at 24 weeks
"Zhang, 2006",Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from china,APLAR Journal of Rheumatology,Outcomes,No outcomes of interest at 24 weeks
"Zhang, 2013",Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis,International journal of clinical pharmacology and therapeutics,Outcomes,No outcomes of interest at 24 weeks
"Zhao, 2017",Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate,Biomedical Research (India),Population,cDMARD na夫e
"Zhou, 2007","Pharmacokinetics and safety of golimumab, a fully human anti-tnf-alpha monoclonal antibody, in subjects with rheumatoid arthritis",Journal of clinical pharmacology,Outcomes,No outcomes of interest